Dynamic Contrast Enhanced Computed Tomography (CT) for Head and Neck Cancer
Not Applicable
Terminated
- Conditions
- Head and Neck Cancer
- Registration Number
- NCT01549379
- Lead Sponsor
- Lawson Health Research Institute
- Brief Summary
For patients undergoing treatment for head and neck cancer, this study will use dynamic contrast-enhanced CT scans to try to determine which lymph nodes in the neck contain cancer and require surgical removal.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
-
Age 18 or older
-
Willing to provide informed consent
-
ECOG performance status 0-2
-
Histologically confirmed squamous cell carcinoma (includes variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma NOS) of the head and neck
-
Tumor stage: Any (T1-T4)
-
Nodal stage:
- N2 or N3 (≥ 3 cm) on pre-treatment imaging for radiotherapy cohort (higher likelihood of requiring neck dissection);
- N1-N3 for surgery cohort. N0 admissible for T4 tumors.
-
Patient assessed at head and neck multidisciplinary clinic (with assessment by radiation oncologist and surgeon), with recommendation for definitive chemoradiation therapy (n=15) or surgery (n=15)
Exclusion Criteria
- Prior history of head and neck cancer within 5 years
- Prior head and neck radiation at any time
- Metastatic disease, or imaging findings suspicious for metastases
- Prior invasive malignant disease unless disease-free for at least 5 years or more, with the exception of non-melanoma skin cancer.
- Pregnant or lactating women
- Contraindication to DCE-CT (e.g. contrast allergy)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Sensitivity and specificity of DCE-CT in predicting the presence of residual lymph node disease after the completion of chemotherapy 8-10 weeks post treatment
- Secondary Outcome Measures
Name Time Method Sensitivity and specificity of DCE-CT in predicting presence of lymph node disease at surgery Approximately 2-6 weeks after enrollment
Trial Locations
- Locations (1)
London Regional Cancer Program
🇨🇦London, Ontario, Canada
London Regional Cancer Program🇨🇦London, Ontario, Canada